 |
|
Experimental Prostate Cancer Drugs Slow Disease Progression
Joan Stephenson, PhD
JAMA. 2001;286:34.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
San Francisco—A new agent shows promise in reducing bone loss and delaying progression of disease in men with advanced prostate cancer that no longer responds to hormone therapy, according to findings presented here at the annual meeting of the American Society of Clinical Oncology. Like other new therapeutics that are emerging in cancer treatment, this experimental drug is intended to target one of the specific molecular pathways that allow the cancerous cells to survive, proliferate, and spread through the body.
Bone metastases in prostate cancer are common and are correlated with morbidity (such as pain) and a poor prognosis. Men with advanced, hormone-refractory prostate cancer now have limited treatment options, said Michael Carducci, MD, of Johns Hopkins Oncology Center, who presented findings from one of two studies involving the drug.
The drug under study, atrasentan, is designed to block the action of endothelin-1, a potent vasoconstrictor . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Endothelin-1-specific Activation of B-type Natriuretic Peptide Gene via p38 Mitogen-activated Protein Kinase and Nuclear ETS Factors
Pikkarainen et al.
J. Biol. Chem. 2003;278:3969-3975.
ABSTRACT
| FULL TEXT
|
